{"url_path":"/sec/tngx/8-k/2026-06-23/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-279788-index.html","accession_number":"0001193125-26-279788","cik":"0001819133","ticker":"TNGX","issuer_name":"Tango Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-279788-index.html","primary_entity_key":"0001819133","primary_entity_name":"Tango Therapeutics, Inc."},"word_count":79,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNo.\n\n  \n\nDescription\n\n99.1\n  \n[Press Release dated June 22, 2026.](d79260dex991.htm)\n\n104\n  \nCover page interactive data file (embedded within the Inline XBRL document)\n\n \n\nSignature\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nTANGO THERAPEUTICS, INC.\n\nDated: June 23, 2026\n \n\n \nBy:\n \n\n/s/ Matthew Gall\n\n \n\n \nName:\n \nMatthew Gall\n\n \n\n \nTitle:\n \nChief Financial Officer"}